A cure is possible for some cancer malignancies, most notably, Hodgkin's lymphoma, breast cancer, and squamous cell carcinoma. However, most malignancies do not seem to be amenable to a potential cure. This article examines the possibility of a cure of these malignancies in a small number of patients and is not a cure by any means. The article addresses the ethics of cure when the life expectancy is less than a few months.
About half (around 47%) of American adults aged 20 and older have at least one malignancy at some time in their lives. The most common malignancies were breast cancer (8.6 million), lung cancer (3.9 million), colon cancer (2.9 million) and prostate cancer (2.2 million). In total, approximately 10.0 million people in the United States were diagnosed with or died from malignancies in 2000. In contrast with breast cancer, which is often a long-term problem, the average lifetime risk of dying from prostate cancer or lung cancer is comparable to the population as a whole.
Some risk factors for malignancies can be modelled by simple causal models, in which environmental, genetic or behavioural factors are associated with certain pathogenetic pathways. Examples of such associations are as follows: excess lifetime weight gain and overweight/obesity; smoking and [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), and high-serum IGF-I levels and lung cancer among men with cancer. In contrast, risk factors for developing malignancies are usually complex and will normally depend on the host's susceptibility and responsiveness to putative causal factors. For example, a link between breast cancer risk and HRT is very likely due to HRT influencing the ovarian risk factor oestrogen.
Malignancies are classified according to the organ or organs in which the primary tumor develops. Most cases of cancer come under the umbrella of malignancies.\n
As there are many cancer types, the signs of cancer depend on the type of cancer. The key signs and symptoms reported by patients are fatigue, unexplained weight loss, cough or difficulty swallowing, and erythema nodosum or skin changes.
Cancer treatment usually includes the use of many types of chemotherapy drugs or cytotoxic therapy. Chemotherapy is often used in the treatment of lymphoma. A wide variety of anti-cancer drugs are used to treat cancer, including protease inhibitors like indinavir, proteasome inhibitors like bortezomib, and thiol alkylating agents like temozolomide. Radiation therapy is used as first-line therapy for breast cancer. More recently, targeted therapies like erlotinib have been used in the treatment of non-small-cell lung cancer and EGFR inhibitors like erlotinib (Tarceva) have been used in the treatment of EGFR mutated non-small-cell lung cancer.
A new type of therapy for cancer patients, which uses the application system of zoeinsights. This procedure, performed over a period of 6 to 12 months, is recommended for the patients who are not suitable for cytotoxic therapy, or other conventional treatment methods. The treatment of cancer patients with zoeinsight system has already been approved in more than 15 medical centers in the UK. This is a new treatment methodology, which does not involve the use of the cytotoxicity. The therapy consists in the combination of a few types of therapies, including those related to the therapeutic use of this system: physiotherapy, ergotherapeutic, immunotherapy, anti-oncological treatment, physiotherapy, and palliative care.
This ZOEINTS application is one of the first available applications of its kind, and so its findings need to be evaluated by experts in clinical trials. While the results presented are encouraging in demonstrating the potential of ZOEINTS for clinical application, further studies with larger samples are needed.
In this cohort of people, no clinically significant adverse events were found from 1-month of use. This data was not gathered in a time frame that could be considered to be "safe to begin therapy" or "safe to continue therapy" or "safe to discontinue therapy." These data should not influence clinical behavior but should be explored and compared to other similar studies to determine if a longer time frame for use and to evaluate efficacy would be safer for all people using this tool.
Zoeinsights application usually treats the following cancers: renal, prostate, lung, breast, skin, thyroid, colon, and gallbladder. The software evaluates the patient’s tumor and identifies different treatment alternatives with great precision. This helps to identify the risks and benefits of treatments in the patient’s disease and helps optimize their dosage.
Results from a recent clinical trial of this paper support the hypothesis that the combination of AIPCs and ZOEINTS may improve patient survival after neoadjuvant treatment.